×
-0.00270096463022507 0.00723472668810288 -0.00643086816720258 -0.0163987138263666 -0.0356913183279743 -0.0658520900321544 -0.0581350482315113 -0.0578778135048232
Stockreport

Capricor to employ peripheral IV administration of cell therapy CAP-1002 in mid-stage DMD study; shares ahead 13% [Seeking Alpha]

CAPRICOR THERAPEUTICS (CAPR)  More Company Research Source: Seeking Alpha
Last capricor therapeutics earnings: 8/9 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF Capricor to employ peripheral IV administration of cell therapy CAP-1002 in mid-stage DMD study; shares ahead 13%Capricor Therapeutics (CAPR+12.8%) plans to administer CAP-1002 intravenously in its upcoming Phase 2 clinical trial, HOPE-2, in boys and young men with Duchenne muscular dystrophy (DMD).In aposter presentation at the Alliance for Regenerative Medicine's Cell and Gene Therapy Meeting on the Mesa, researchers from the company and Cedars-Sinai Medical Center reported encouraging preclinical data that showed IV administration of cardiosphere-derived cells (CDCs) increased exercise capacity and diaphragm function. The results also showed that CDCs predominantly distribute to the lungs after injection and are cleared within three weeks. Dosing at more than 2.5x the human equivalent dose for HOPE-2 was observed to be safe.Enrollment in HOPE-2 should commence in Q1 2018.The previous method of administering CAP-1002 was infusion directly into the patient's coronary artery via a cat [Read more]

IMPACT SNAPSHOT EVENT TIME: CAPR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
CAPR alerts
from News Quantified
Opt-in for
CAPR alerts

from News Quantified
Opt-in for
CAPR alerts

from News Quantified